# Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients

> **NCT06046794** · NA · RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 100 (estimated)

## Conditions studied

- Cancer Of Pancreas

## Interventions

- **OTHER:** Analyze of GemCore status

## Key facts

- **NCT ID:** NCT06046794
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046794, "Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06046794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*